Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02019368
Other study ID # eki-843
Secondary ID
Status Completed
Phase N/A
First received December 18, 2013
Last updated August 17, 2015
Start date November 2013
Est. completion date April 2015

Study information

Verified date August 2015
Source Hiroshima University
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo controlled, crossover study to determine the antioxidant effect of aged garlic extract. This study will also compare the oxidative status in heavy smokers with that in non-smokers.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria:

- Smoking (at least 20 cigarettes per day) or non-smoking (more than 20 years)

Exclusion Criteria:

- Under medication for chronic disease

- Garlic allergy

- Engaging in vigorous exercise

- Taking drugs or functional food that may possess antioxidant property

- Participation in any clinical trial within 90 days of the commencement of the trial

- Renal or hepatic dysfunction

- Heart disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo

Aged garlic extract


Locations

Country Name City State
Japan Hiroshima University Hiroshima

Sponsors (2)

Lead Sponsor Collaborator
Hiroshima University Wakunaga Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary 8-hydroxydeoxyguanosine (8-OHdG) Every 4 weeks (Overall 12 weeks) No
Secondary High sensitive CRP Every 4 weeks (Overall 12 weeks) No
Secondary Blood pressure Every 4 weeks (Overall 12 weeks) No
Secondary Indices of the second derivative of photoplethysmogram (SDPTG) Every 4 weeks (Overall 12 weeks) No